T3D Therapeutics Awarded SBIR Phase 2 Grant for Alzheimer’s Disease Drug Testing from The National Institute On Aging

T3D Therapeutics, Inc., a Research Triangle Park, NC-based developer of Alzheimer’s disease therapies announced today that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) Phase 2 grant for the clinical development of T3D–959, a small molecule nuclear receptor agonist, for the treatment of Alzheimer’s disease. This award provides the company with an estimated $1.8 million in funding over two years. The award will support a Phase 2a clinical trial evaluating the efficacy and safety of T3D–959 in mild-to-moderate Alzheimer’s patients.  T3D–959 is a promising new, and potentially disease-modifying therapeutic for Alzheimer’s disease. The drug has displayed multi-faceted effectiveness on memory, motor function, inflammation, neuronal cell death, beta amyloid production and tau alteration in pre-clinical studies.

Commenting on the award, T3D Therapeutics’ CEO John Didsbury said, “The National Institute on Aging’s support will enable us to test our novel approach to developing an Alzheimer’s disease drug therapy that has the potential to slow, stop or reverse the progression of disease. This award is reflective of the goal of the National Plan to address Alzheimer’s disease of finding effective therapies to prevent and effectively treat Alzheimer’s by
2025.”

Read the full press release: here.

get the latest

X
X